Founders Capital Management (Texas)’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9K | Hold |
12,000
| – | – | 0.01% | 278 |
|
|
2025
Q1 | $5.42K | Buy |
+12,000
| New | +$5.42K | ﹤0.01% | 305 |
|
|
2024
Q4 | – | Sell |
-15,000
| Closed | -$13.6K | – | 381 |
|
|
2024
Q3 | $13.6K | Buy |
15,000
+7,000
| +88% | +$6.34K | 0.01% | 268 |
|
|
2024
Q2 | $7.98K | Hold |
8,000
| – | – | 0.01% | 296 |
|
|
2024
Q1 | $11.8K | Hold |
8,000
| – | – | 0.01% | 275 |
|
|
2023
Q4 | $8.72K | Hold |
8,000
| – | – | 0.01% | 297 |
|
|
2023
Q3 | $9.44K | Hold |
8,000
| – | – | 0.01% | 298 |
|
|
2023
Q2 | $11.3K | Hold |
8,000
| – | – | 0.01% | 297 |
|
|
2023
Q1 | $12K | Hold |
8,000
| – | – | 0.01% | 298 |
|
|
2022
Q4 | $9K | Hold |
8,000
| – | – | 0.01% | 308 |
|
|
2022
Q3 | $9K | Hold |
8,000
| – | – | 0.01% | 305 |
|
|
2022
Q2 | $13K | Hold |
8,000
| – | – | 0.01% | 282 |
|
|
2022
Q1 | $20K | Hold |
8,000
| – | – | 0.01% | 211 |
|
|
2021
Q4 | $20K | Buy |
8,000
+3,030
| +61% | +$7.58K | 0.01% | 211 |
|
|
2021
Q3 | $13K | Hold |
4,970
| – | – | 0.01% | 249 |
|
|
2021
Q2 | $14K | Hold |
4,970
| – | – | 0.01% | 238 |
|
|
2021
Q1 | $12K | Hold |
4,970
| – | – | 0.01% | 232 |
|
|
2020
Q4 | $9K | Buy |
+4,970
| New | +$9K | 0.01% | 254 |
|
|
2020
Q1 | $4K | Hold |
4,970
| – | – | ﹤0.01% | 277 |
|
|
2019
Q4 | $4K | Hold |
4,970
| – | – | ﹤0.01% | 300 |
|
|
2019
Q3 | $5K | Hold |
4,970
| – | – | ﹤0.01% | 291 |
|
|
2019
Q2 | $5K | Hold |
4,970
| – | – | ﹤0.01% | 297 |
|
|
2019
Q1 | $7K | Buy |
+4,970
| New | +$7K | 0.01% | 281 |
|